1) Teniposide/therapeutic use
替尼泊甙/治疗应用
2) Teniposide
替尼泊甙
1.
Effects of Teniposide on Cell Cycle Phase and Apoptosis of Gastric Carcinoma Cell Lines;
替尼泊甙对胃癌细胞凋亡及细胞周期的影响
2.
Clinical effect of temozolomide vs teniposide and lomustine in patients with malignant glioma;
单用替莫唑胺与替尼泊甙联合洛莫司汀治疗恶性胶质瘤的比较
3.
Effects of teniposide combined with other anticancer drugs on proliferation of BGC-823 cell lines in vitro;
替尼泊甙联合其他抗肿瘤药对BGC-823细胞体外增殖的影响
3) VM-26
替尼泊甙
1.
The influences of Actinomycin D and VM-26 on proliferation in rat glioma cell line C_6;
放线菌素D和替尼泊甙对大鼠胶质瘤细胞增殖影响的实验研究
2.
Objective To study the therapeutic effect of actimomycin D (ACTD) and VM-26 on rat C6 glioma invivo.
目的研究放线菌素D(ACTD)、替尼泊甙(VM-26)对大鼠胶质瘤细胞增殖的体内治疗效果。
3.
Objective To investigate the curative effect of intravenous chemotherapy with BVD(BCNU+VM-26+DDP) in treating brain gliomas after surgical excision.
目的探讨脑胶质瘤术后应用BVD方案(卡氮芥+替尼泊甙+顺铂)静脉化疗的临床疗效。
4) tineposide
替尼泊甙
1.
Enhancement of cisplatin on cytocidal effect of tineposide against small cell lung cancer cell line;
顺铂增强替尼泊甙杀伤小细胞肺癌细胞系的作用
2.
Objective: To investigate the expressions of topoisomeraseII and transcription factor Sp1 (Specificity protein-1) in theprocess of cisplatin influencing on tineposide killing the smallcell lung cancer cells.
目的:探讨DNA拓扑异构酶II (topoisomerase II, Topo II)及特化蛋白1(Specificity protein-1, Sp1)在顺铂(cisplatin,CDDP)对替尼泊甙(tineposide, VM-26)杀伤小细胞肺癌(small cell lung cancer, SCLC)细胞影响过程中的表达。
5) Topotecan/therapeutic use
托泊替康/治疗应用
6) Gefitinib/therap eutic application
吉非替尼/治疗应用
补充资料：替尼泊甙
分子式：C32H32O13S
分子量：暂无
CAS号：29767-20-2
性质：暂无
制备方法：暂无
用途：用于白血病、恶性淋巴瘤、神经母细胞瘤、膀胱癌和小细胞肺癌。
分子量：暂无
CAS号：29767-20-2
性质：暂无
制备方法：暂无
用途：用于白血病、恶性淋巴瘤、神经母细胞瘤、膀胱癌和小细胞肺癌。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条